Sun Pharmaceutical Industries Ltd News

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Stocks to Watch today, March 17: RIL, Tata Motors, Sun Pharma, RVNL, GMDC

Stocks to Watch today, March 17: Reliance Industries, Tata Motors, Sun Pharma, RVNL, GMDC, RailTel, and Sagar Cements are among the top stocks to watch today

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Sun Pharma up 5% in 1 week, nears 52-week high; what's driving this stock?

Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.

Sun Pharma, Hindustan Aeronautics top stock picks for today; check targets

Sun Pharma and Hindustan Aeronautics are among the top stock picks by Rajesh Bhosale of Angel One

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Pharma stocks in demand; Torrent hits new high; Natco up 6% on huge volumes

At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.

US market remained a drag for Indian pharma in Q3 amid pricing pressure

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

New launches to keep growth momentum healthy for Sun Pharma stock

Strong Q3 results and relief from lower US reciprocal taxes lift Sun Pharma shares, prompting brokerages to upgrade earnings outlook and target prices

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Sun Pharma sees US generics stabilising, pins growth on innovation push

Sun Pharmaceutical Industries expects pressure on its US generics business to ease as compliance improves, while focusing growth efforts on innovation-led therapies

Sun Pharma growth momentum to sustain post Q3 profit jump, say brokerages

Sun Pharma reported a 16 per cent year-on-year (Y-o-Y) growth in its consolidated profit after tax (PAT) at ₹3,369 crore for Q3FY26

Stocks to Watch today, Feb 1: Defence, Infra, Meesho, Ola, Sun Pharma

Stocks to Watch today, February 1, 2026: From Glenmark Pharma to Ola Electric, here are few shares that will remain in focus

Sun Pharma Q3FY26 profit rises 16% on new launches, revenue climbs 13.5%

US generics remain under pressure while API revenues decline during the quarter

Q3 results: Sun Pharma, GAIL, IDFC first bank, Delhivery, 72 more on Jan 31

Q3FY26 company results: Firms including Bharat Dynamics, ZF Steering Gear India, R R Kabel, Finolex Industries and Reliance Infrastructure are also to release their October-December earnings today

These are most overbought, oversold stocks on BSE, NSE ahead of Budget 2026

A technical scan on Nifty 500 stocks reveals that 6 shares were trading in overbought territory based on the RSI parameter, while 66 languished in the oversold zone a day ahead of the Union Budget.

Sun Pharma Q3 Preview: Profit, revenue and key factors to watch in Dec qtr

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

China halts import, sale of Sun Pharma's Alzheimer's drug after inspection

In 2024, the ​USFDA issued a warning letter to Sun Pharma alleging 'significant violations' of 'current good manufacturing practice' ‍regulations for pharma made at the same production site in India

Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA

Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug Administration. As per its latest Enforcement Report, the US-based arm of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication to treat dandruff and skin conditions with inflammation and itching. The Princeton (New Jersey)-based Sun Pharmaceutical Industries Inc is recalling 24,624 bottles of Fluocinolone Acetonide Solution Topical Solution for "Failed Impurities/Degradation Specifications", the US health regulator said. The company initiated the Class III nationwide (US) recall on December 30, 2025. The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris. Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results f

Sun Pharma terms $10 billion Organon acquisition reports 'speculative'

Sun Pharmaceutical said reports of a $10 billion acquisition of US-based Organon are speculative, adding there is no material information requiring disclosure to exchanges